ADOA Clinical Trials: What Are the New Treatments?

While there is currently no FDA-approved cure for Autosomal Dominant Optic Atrophy (ADOA), research is actively working toward potential treatments. Several new therapies aimed at slowing vision loss or restoring function are currently in the preclinical testing phase ^[1]. Preclinical research means these therapies are being tested in laboratories and animal models to ensure they are safe and effective before they can move into human clinical trials—a process that can take several years. These investigational treatments generally fall into three main categories: gene-targeting therapies (like ASOs), gene replacement therapies, and laboratory compounds aimed at protecting the mitochondria in the eye ^[2][3].

Antisense Oligonucleotides (ASOs)

Because ADOA is most often caused by mutations in the OPA1 gene that lead to a shortage of the OPA1 protein (a condition called haploinsufficiency), researchers are looking for ways to encourage the body to make more of it ^[1][4].

Antisense oligonucleotides (ASOs) are short, synthetic strings of genetic code designed to bind to a cell’s messenger RNA and change how proteins are made. They are typically delivered directly to the eye via an intravitreal injection (a shot into the fluid of the eye). A prominent example of this technology in ADOA research was STK-002, created by Stoke Therapeutics. STK-002 was designed to adjust how the OPA1 gene is read by the cell, preventing a natural “stop” signal to produce more functional OPA1 protein ^[1].

While STK-002 successfully increased OPA1 protein levels in laboratory studies, its clinical development was paused in early 2024. However, the foundational science behind ASOs remains highly relevant, and other researchers continue to explore this approach as a way to correct OPA1 mutations ^[1][5].

Gene Therapy

Another major area of research is gene replacement therapy. This approach uses a harmless virus (often an adeno-associated virus, or AAV) to deliver a healthy, functional copy of the OPA1 gene directly into the cells of the retina ^[1]. Like ASOs, these therapies require direct administration to the eye, either through an intravitreal injection or subretinal surgery (placing the therapy underneath the retina). While generally safe in other approved eye treatments, viral vectors do carry standard risks, such as intraocular inflammation.

Researchers are particularly focused on variant-agnostic gene therapies. This means that instead of having to design a custom therapy for each of the hundreds of specific OPA1 mutations, the therapy is designed to provide a working copy of the gene that can help regardless of a patient’s exact genetic variant ^[5][2].

Mitochondrial Support and Laboratory Compounds

While gene therapies aim to fix the root cause of ADOA, other approaches focus on protecting the retinal ganglion cells—the cells that connect the eye to the brain—from damage caused by malfunctioning mitochondria ^[6].

• Nicotinamide (Vitamin B3): Laboratory research suggests that boosting the NAD+/NADH ratio (vital molecules for cellular energy) may protect retinal ganglion cells from degeneration in ADOA models ^[6]. Warning: High-dose supplements like Vitamin B3 can have serious side effects, including severe liver toxicity. Never self-medicate without consulting your neuro-ophthalmologist to ensure safety and proper dosage.
• Idebenone: This medication is approved in some countries for Leber Hereditary Optic Neuropathy (LHON), another mitochondrial eye disease. While some ADOA patients are prescribed Idebenone “off-label,” rigorous clinical evidence proving its effectiveness specifically for ADOA is still lacking, though it remains a topic of community interest and ongoing observation.
• Laboratory Research Compounds: Scientists are screening molecules (like Paromomycin and Mdivi-1) that can correct mitochondrial shape and block pathways leading to cell death ^[7][8][9]. These are not available drugs; they are experimental tools used by researchers in test tubes and animal models to identify future therapeutic targets.

Preparing for Trials: Patient Registries

If you want to participate in future clinical trials, the most important proactive step you can take today is joining patient registries ^[10].

• Patient Registries: Register with the Coordination of Rare Diseases at Sanford (CoRDS) registry, which tracks natural history data vital for researchers to understand disease progression ^[11][12].
• Advocacy Groups: Organizations like the Cure ADOA Foundation are a crucial lifeline for patients, connecting families to registries and providing updates on upcoming trials.
• Tracking Trials: You can actively search ClinicalTrials.gov using the term “Autosomal Dominant Optic Atrophy” or “OPA1” to monitor newly recruiting human trials.